SCHEMBL4861959

SCHEMBL4861959

CC(C)(C)[Si](C)(C)O[C@@H]1CC(OCc2ccccc2)C[C@@H](O[Si](C)(C)C(C)(C)C)C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.39
CTSL P07711 2/20 0.37
CTSB P07858 2/20 0.37
CTSK P43235 2/20 0.37
OPRM1 P35372 2/20 0.36
OPRL1 P41146 2/20 0.36
PSEN1 P49768 4/20 0.35
PSEN2 P49810 4/20 0.35
APH1B Q8WW43 4/20 0.35
NCSTN Q92542 4/20 0.35
APH1A Q96BI3 4/20 0.35
PSENEN Q9NZ42 4/20 0.35
NAAA Q02083 2/20 0.35
TMEM97 Q5BJF2 1/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
PRMT8 Q9NR22 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
MAPT P10636 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4862984 0.87 NAAA (0.37) SIGMAR1CTSLCTSBCTSKOPRM1
SCHEMBL21028938 0.85 CTSL (0.41) SIGMAR1CTSLCTSBCTSKOPRM1
SCHEMBL21029509 0.85 CTSL (0.41) SIGMAR1CTSLCTSBCTSKOPRM1
SCHEMBL22906947 0.85 CTSL (0.41) SIGMAR1CTSLCTSBCTSKOPRM1
SCHEMBL14107853 0.84 CTSL (0.36) SIGMAR1CTSLCTSBCTSKOPRM1
SCHEMBL14107854 0.82 OPRM1 (0.33) SIGMAR1CTSLCTSBCTSKOPRM1
SCHEMBL4912191 0.82 NAAA (0.36) SIGMAR1CTSLCTSBCTSKOPRM1
SCHEMBL4912199 0.82 NAAA (0.36) SIGMAR1CTSLCTSBCTSKOPRM1
SCHEMBL6575168 0.82 NAAA (0.36) SIGMAR1CTSLCTSBCTSKOPRM1
SCHEMBL4912188 0.82 NAAA (0.36) SIGMAR1CTSLCTSBCTSKOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402688-B2 2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin D derivative WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-07-22 US disclosed
US-7402688-B2 2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin D derivative WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2008-07-22 US disclosed
US-20060160779-A1 2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin d derivative WISCONSIN ALUMNI RESEARCH FOUNDATION 2006-07-20 US disclosed
EP-1559708-A1 2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE Shimizu, Masato (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160779-A1 2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin d derivative CYP24A1, CYP2R1, VDR SIGMAR1 2106/4885CTSL 2998/4885CTSB 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.